argenx SE (EBR:ARGX)
897.60
+18.40 (2.09%)
Aug 26, 2026, 5:39 PM CET
argenx SE Revenue
argenx SE had revenue of $1.54B USD in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.51% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.33B
Revenue Growth
+70.51%
P/S Ratio
11.82
Revenue / Employee
$2.86M
Employees
1,863
Market Cap
54.98B EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 8.52B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |
argenx SE News
- 10 hours ago - Argenx price target raised to $1,415 from $1,350 at Wells Fargo - TheFly
- 12 hours ago - Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story - The Motley Fool
- 12 hours ago - Argenx upgraded to Buy from Neutral at UBS - TheFly
- 2 days ago - Argenx downgraded to Hold at Deutsche Bank after almost 50% advance - TheFly
- 2 days ago - Argenx downgraded to Hold from Buy at Deutsche Bank - TheFly
- 8 days ago - ARGX Maintains Buy Rating -- Price Target Raised to $1,095 by Truist Securities - GuruFocus
- 8 days ago - ARGX Maintained by RBC Capital -- Price Target Raised to $1100 - GuruFocus
- 8 days ago - ARGX Maintained by Citizens -- Price Target Raised to $1200 - GuruFocus